Evidence map›Paper›PMID 34312688›Full record

ArticleCardiovascular and interventional radiology2021

Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study.

Andras Bibok, Rahul Mhaskar, Rohit Jain, Jingsong Zhang, Jessica Frakes, Sarah Hoffe, Ghassan El-Haddad, Nainesh Parikh, Altan Ahmed, Mayer N Fishman and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Andras BibokDiagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, USA.
Rahul MhaskarDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Rohit JainGenitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Jingsong ZhangGenitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Jessica FrakesRadiation Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Sarah HoffeRadiation Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Ghassan El-HaddadDiagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, USA.
Nainesh ParikhDiagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, USA.
Altan AhmedDiagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, USA.
Mayer N FishmanDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Junsung ChoiDiagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, USA.
Bela KisDiagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, USA. bela.kis@moffitt.org.ORCID http://orcid.org/0000-0002-8898-650X
Moffitt Cancer Center · USUniversity of South Florida · USSemmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe management of Renal cell carcinoma (RCC) patients with liver metastases is challenging. Liver-directed therapy, such as Transarterial radioembolization (TARE), is a reasonable option for these patients; however, its safety and efficacy are not well characterized. This study evaluated the safety and efficacy of TARE in patients with liver-dominant metastatic RCC. MATERIALS AND

methodsThis is a retrospective, single-center study. Thirty-eight patients' medical records were reviewed who underwent TARE between January 1, 2009, and December 31, 2019, in a tertiary cancer center. Two were excluded from further analysis. Thirty-six patients received 51 TARE treatments. Median follow-up time was 18.2 months. Imaging data were evaluated using mRECIST or RECIST 1.1 criteria. Toxicities, treatment responses, liver progression-free survival (LPFS), and median overall survival (OS) were calculated. Univariate and multivariate analyses were conducted to reveal predictors of OS.

resultsMedian OS from TARE was 19.3 months (95% CI, 22.6-47.4) and from diagnosis of liver metastases was 36.5 months (95% CI: 26.4-49.8). Mild, grade 1 or 2, biochemical toxicity developed in 27 patients (75%). Grade 3-4 toxicity was noted in two patients (5.5%). The objective response rate was 89%; the disease control rate was 94% (21 complete response, 11 partial response, two stable disease, and two progressive disease). Univariate and multivariate analyses showed longer survival in patients who had objective response, lower lung shunt fraction, and better baseline liver function.

conclusionsTARE is safe and effective and led to promising overall survival in patients with liver-dominant metastatic RCC. LEVEL OF EVIDENCE: Level 3, retrospective cohort study.

Indexed as

Carcinoma, HepatocellularCarcinoma, Renal CellEmbolization, TherapeuticKidney NeoplasmsLiver NeoplasmsHumansLiverRetrospective StudiesTreatment OutcomeYttrium RadioisotopesYttrium RadioisotopesHepatic neoplasmsInterventional radiologyRenal cell carcinomaTherapeutic embolizationYttrium radioisotopes

Identifiers

PMID34312688
OpenAlexW3184535478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.